Veradermics shares climb on positive VDPHL01 data and raised price target
Veradermics Inc shares gained 2.5% in midday trading after the company reported positive 12-month results from Part B of its Phase 2/3 Study ’302,’ a randomized, double-blind, placebo-controlled trial of VDPHL01 in 519 men with mild-to-moderate pattern hair loss. At Month 12, twice-daily treatment increased non-vellus hair count by 43.9 hairs/cm² from baseline, while once-daily dosing produced a gain of 29.7 hairs/cm². The data showed continued improvement in the twice-daily arm and maintenance in the once-daily arm, while VDPHL01 remained generally well tolerated with no new safety signals.
Leerink Partners also lifted its Veradermics price target to $150 from $135 following the data release, adding to the positive tone. Together with previously reported positive topline results from Study ’302’ Part A and Phase 3 Study ’304,’ these findings put VDPHL01 in position to potentially become the first FDA-approved oral pill in nearly 30 years for pattern hair loss. Veradermics also intends to report data from its female pattern hair loss Study ’306’ in the first half of 2027, a near-term pipeline catalyst that analysts may factor into updated valuations.
The S&P 500 jumped more than 1.7% as dip buyers returned to equities after the Nasdaq fell over 5% last week, its fourth consecutive down week. All 11 S&P sectors traded higher in a broad-based rally. A stronger-than-expected October jobs report also provided macro support: non-farm payrolls rose 165,000, the unemployment rate slipped to 4.1%, and average hourly earnings increased 0.4% month-over-month. The data nonetheless kept the possibility of a December Federal Reserve rate move in focus.
For MANE shares on the day, the combination of company-specific clinical momentum and a favorable macro backdrop proved especially constructive. With the stock at $142.21, near its 52-week high of $146.57, the robust Phase 2/3 long-term data, the analyst price-target increase and the broader market rebound formed a supportive backdrop that pushed the shares well above their $135.71 opening price.
AI-assisted article reviewed by an editor; further details are in our terms and conditions.